Dr. Jurgen Lademann Accepts Post As Chairman Of Biozoom's Scientific Advisory Board

Internationally renowned professor validated and led nine successful studies using Biozoom scanner, sees many consumer and professional applications of technology

Jun 06, 2013, 09:33 ET from Biozoom

KASSEL, Germany, June 6, 2013 /PRNewswire/ -- Biozoom (OTC QB: BIZM), creator of the world's first portable, handheld device for real-time biofeedback, announced today that Dr. Jurgen Lademann, has accepted an appointment as Chairman of the Biozoom Scientific Advisory Board. "We are pleased and honored that a scholar of  Dr. Lademann's caliber and intellect will be advising the technological evolution of Biozoom, said CEO Hardy Hoheisel. "As Director of Charite Berlin's Center of Experimental and Applied Cutaneous Physiology Dr. Lademann has seen firsthand the remarkable benefits Biozoom can have not only in research, but on improving the health and wellness of people's lives."

An internationally recognized researcher of the connections among dermatology, pharmacology and biophysics, Dr. Lademann is one of the leading experts on non-invasive measurement of biomarkers in human skin. Dr. Lademann has tested and used the Biozoom scanner for more than five years. "Biozoom's support of and cooperation with the Center has been invaluable. After we validated its reliability in the lab, our studies have proved its effectiveness in the field. We have used it to advance our scientific work, helping us to clarify the physiological function of antioxidants in the skin. The scanner has generated a great deal of interest wherever it has been used, and I receive inquiries about it almost every day, it seems."

Dr. Lademann studied at the Martin-Luther University, Halle, and Moscov-Lomonosov University, after which he was appointed Group and Project Manager at the Institute of Optics and Spectroscopy of the Academy of Science. Since 1998 he has been Head of the Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Charite -  Berlin. In 2000, he was appointed Professor of Dermatology at Charite - Universitatsmedizin Berlin. He is the editor of the international journal "Skin Pharmacology and Applied Skin Physiology" and board member of the German Federal Institute of Risk Assessment, Berlin, Germany. Dr. Lademann is also the President of the "International Society of Skin Pharmacology and Physiology" and Member of the Experts Team for Risk Assessment of Nanoparticles in Cosmetic Products with ECETOC AISBL, Brussels.

"I look forward to helping guide the development of new capabilities and applications for hand held reflective spectroscopy," said Dr. Lademann. "The potential for widespread adoption of Biozoom's product is great."

About Biozoom
Biozoom is an innovative technology development company, specializing in the commercialization of our advances in mobile spectroscopy.  Our intellectual property portfolio and ongoing research are positioned to apply Biozoom's technology breakthroughs to a wide range of markets. Our first consumer product, the Biozoom scanner, gives people the feedback they need to manage their health, wellness and fitness on demand.  Tested in leading health institutions, our scanner is the first of its kind—a handheld, transdermal device for measuring biomarkers, including antioxidant levels, at the click of a button. Scan results— and customized wellness coaching based on those biomarkers— are sent instantly to a smartphone or online account.  The scanner will enable leaders in the health and wellness industry to create new levels of customer loyalty and revenues as a result. For more information, visit www.biozoom.net.

This press release contains "forward-looking statements". Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, and specifically references to future potential purchase orders and re-orders from consumers and distributors. The reader can identify these forward-looking statements by forward-looking words such as "may," "will," "expect," "potential," "anticipate," "forecast," "believe," "estimate," "project," "plan," "continue" or similar words. The reader should read statements that contain these words carefully because they discuss future expectations, contain projections of future results of operations or of financial condition, or state other forward-looking information. Forward-looking statements include, but are not limited to, statements regarding potential products, customers, revenues, expansion efforts, and future plans and objectives of Biozoom, Inc. ("Biozoom"). The risk factors listed in our disclosure documents and the cautionary language therein provide examples of risks, uncertainties and events that may cause actual results to differ materially from the expectations and projections described by Biozoom in its forward-looking statements. Actual results relating to, among other things, product launch, sales, customer acceptance and market share could differ materially from those currently anticipated in such statements. Factors affecting forward-looking statements include: consumer preferences, competition from more established brands, ability to develop market share; changes in the operating costs; changes in economic conditions, foreign exchange and other financial markets; changes of the interest rates on borrowings; changes in the investments levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Biozoom operates; technological, mechanical and operational difficulties encountered in connection with Biozoom's development activities; and labor relation matters and costs. The reader should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Biozoom from time to time with the Securities and Exchange Commission and other regulatory authorities.

SOURCE Biozoom